JP2024515240A5 - - Google Patents

Info

Publication number
JP2024515240A5
JP2024515240A5 JP2023561645A JP2023561645A JP2024515240A5 JP 2024515240 A5 JP2024515240 A5 JP 2024515240A5 JP 2023561645 A JP2023561645 A JP 2023561645A JP 2023561645 A JP2023561645 A JP 2023561645A JP 2024515240 A5 JP2024515240 A5 JP 2024515240A5
Authority
JP
Japan
Prior art keywords
item
nucleic acid
acid molecule
hla
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515240A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023685 external-priority patent/WO2022216832A1/en
Publication of JP2024515240A publication Critical patent/JP2024515240A/ja
Publication of JP2024515240A5 publication Critical patent/JP2024515240A5/ja
Pending legal-status Critical Current

Links

JP2023561645A 2021-04-07 2022-04-06 Mhc-i病の治療に使用するための組成物 Pending JP2024515240A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171672P 2021-04-07 2021-04-07
US63/171,672 2021-04-07
PCT/US2022/023685 WO2022216832A1 (en) 2021-04-07 2022-04-06 A composition for use in treating mhc-1-opathies

Publications (2)

Publication Number Publication Date
JP2024515240A JP2024515240A (ja) 2024-04-08
JP2024515240A5 true JP2024515240A5 (cg-RX-API-DMAC7.html) 2025-03-21

Family

ID=81580496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561645A Pending JP2024515240A (ja) 2021-04-07 2022-04-06 Mhc-i病の治療に使用するための組成物

Country Status (10)

Country Link
US (2) US12370257B2 (cg-RX-API-DMAC7.html)
EP (1) EP4320166A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024515240A (cg-RX-API-DMAC7.html)
KR (1) KR20230167355A (cg-RX-API-DMAC7.html)
CN (1) CN117321084A (cg-RX-API-DMAC7.html)
AU (1) AU2022256043A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215902A1 (cg-RX-API-DMAC7.html)
IL (1) IL306046A (cg-RX-API-DMAC7.html)
MX (1) MX2023011720A (cg-RX-API-DMAC7.html)
WO (1) WO2022216832A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL248777B1 (pl) * 2024-03-05 2026-01-26 Inst Immunologii I Terapii Doswiadczalnej Im Ludwika Hirszfelda Polskiej Akademii Nauk Sposób określania ciężkości reumatoidalnego zapalenia stawów na podstawie pomiaru stężenia białka ERAP2
CN118047824B (zh) * 2024-04-01 2024-06-28 北京瑞博奥医药科技有限公司 二烷基膦酸在寡核苷酸合成中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009547A2 (en) 2010-07-14 2012-01-19 The Regents Of The University Of California Biomarkers for diagnosis of transient ischemic attacks
WO2012047294A2 (en) 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
US8969254B2 (en) 2010-12-16 2015-03-03 Dana-Farber Cancer Institute, Inc. Oligonucleotide array for tissue typing
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗-hla-b*27抗體及其用途
ES2762403T3 (es) 2012-04-26 2020-05-25 Stichting Vumc Biomarcadores
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
KR101748867B1 (ko) 2013-04-19 2017-06-20 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 자동화 시스템
EP3489369B1 (en) 2013-06-25 2020-10-28 Turun yliopisto Method of predicting risk for type 1 diabetes
US9907833B2 (en) 2013-07-25 2018-03-06 University Of Florida Research Foundation, Incorporated Use of relaxin to treat placental syndromes
US10927412B2 (en) 2013-10-01 2021-02-23 The Regents Of The University Of California Endometriosis classifier
US10166210B2 (en) 2014-06-12 2019-01-01 Nsabp Foundation, Inc. Methods of subtyping CRC and their association with treatment of colon cancer patients with oxaliplatin
HK1257443A1 (zh) 2015-08-21 2019-10-18 The Children's Hospital Of Philadelphia 治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
GB201609712D0 (en) 2016-06-03 2016-07-20 Babraham Inst Disease targets and biomarkers
US20190375842A1 (en) 2018-01-04 2019-12-12 Vanderbilt University Check point inhibition in organ fibrosis
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US11632728B2 (en) 2019-07-18 2023-04-18 Qualcomm Incorporated Directional measurements for sidelink synchronization signal transmission
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
WO2021113805A1 (en) 2019-12-05 2021-06-10 The General Hospital Corporation Multi-biomarker prediction models for multiple infection episodes following blunt trauma

Similar Documents

Publication Publication Date Title
US20250115907A1 (en) Compositions and methods for inhibiting gene expression of lpa
ES2629747T3 (es) Inducción de la omisión de exones en células eucarióticas
JP7531514B2 (ja) 操作されたmRNA配列及びその使用
US20190062740A1 (en) COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS
US20130331433A1 (en) Mirna modulators of thermogenesis
JP2021091737A (ja) 抗vegfで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法
TW202018081A (zh) 用於B型肝炎病毒感染之RNAi藥劑
JP2018527013A (ja) アレル選択的な遺伝子編集およびその使用
JP2009537129A (ja) エキソンスキッピングを誘発する為の手段及び方法
JP2023536437A5 (cg-RX-API-DMAC7.html)
TW201209163A (en) Treatment of BCL2 binding component 3 (BBC3) related diseases by inhibition of natural antisense transcript to BBC3
JP6286050B2 (ja) トリインフルエンザウイルスのmiRNAとその同定、検出および使用
JP2023526328A5 (cg-RX-API-DMAC7.html)
JP2023538630A (ja) B型肝炎ウイルス感染症を処置するためのa1cf阻害剤の使用
US20180112218A1 (en) Targeting Hepatitis B Virus (HBV) Host Factors
TWI670064B (zh) 抗病毒劑及治療病毒感染之方法
WO2024251725A1 (en) Oligonucleotides targeting gal3st1
CA3237033A1 (en) Methods of treating headaches and migraines with sodium voltage-gated channel alpha subunit 11 (scn11a) inhibitors
US20230025878A1 (en) Methods Of Treating A Metabolic Disorder With Mitogen-Activated Protein Kinase Kinase Kinase 15 (MAP3K15) Inhibitors
WO2004093778A2 (en) Oligonucleotides that block toll-like receptors
WO2013188824A2 (en) Hexim-1 as a target of leptin signaling to regulate obesity and diabetes
CN112779252B (zh) 靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸
JP2022525456A5 (cg-RX-API-DMAC7.html)
US20230108957A1 (en) Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors
JP2025507279A5 (cg-RX-API-DMAC7.html)